Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial - PubMed
6 hours ago
- #prognostic marker
- #ctDNA
- #breast cancer
- Baseline ctDNA positivity is significantly associated with inferior overall survival (HR 2.12, p = 0.043) and shorter survival durations across all endpoints in early breast cancer.
- Trends toward improved outcomes were observed in patients who cleared ctDNA during neoadjuvant therapy, though statistical significance was not reached, likely due to limited sample size.
- These findings support baseline ctDNA as a prognostic marker in early breast cancer, while ctDNA clearance may reflect treatment efficacy, but further validation in larger trials is needed.